Your browser doesn't support javascript.
loading
Treatment for moderate to severe atopic dermatitis in alpine and moderate maritime climates differentially affects helper T cells and memory B cells in children.
Heeringa, J J; Fieten, K B; Bruins, F M; van Hoffen, E; Knol, E F; Pasmans, S G M A; van Zelm, M C.
Afiliación
  • Heeringa JJ; Department of Immunology, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
  • Fieten KB; Department of Pediatrics, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
  • Bruins FM; Department of Dermatology and Allergology, University Medical Center, Utrecht, The Netherlands.
  • van Hoffen E; Merem Dutch Asthma Center Davos, Davos, Switzerland.
  • Knol EF; Swiss Institute of Allergy and Asthma Research (SIAF), University of Zürich, Davos, Switzerland.
  • Pasmans SGMA; Department of Dermatology and Allergology, University Medical Center, Utrecht, The Netherlands.
  • van Zelm MC; Department of Dermatology and Allergology, University Medical Center, Utrecht, The Netherlands.
Clin Exp Allergy ; 48(6): 679-690, 2018 06.
Article en En | MEDLINE | ID: mdl-29575251
BACKGROUND: Treatment of atopic dermatitis (AD) is focused on topical anti-inflammatory therapy, epidermal barrier repair and trigger avoidance. Multidisciplinary treatment in both moderate maritime and alpine climates can successfully reduce disease activity in children with AD. However, it remains unclear whether abnormalities in B cell and T cell memory normalize and whether this differs between treatment strategies. OBJECTIVE: To determine whether successful treatment in maritime and alpine climates normalizes B- and T lymphocytes in children with moderate to severe AD. METHODS: The study was performed in the context of a trial (DAVOS trial, registered at Current Controlled Trials ISCRTN88136485) in which eighty-eight children with moderate to severe AD were randomized to 6 weeks of treatment in moderate maritime climate (outpatient setting) or in the alpine climate (inpatient setting). Before and directly after treatment, disease activity was determined with SA-EASI and serum TARC, and T cell and B cell subsets were quantified in blood. RESULTS: Both treatment protocols achieved a significant decrease in disease activity, which was accompanied by a reduction in circulating memory Treg, transitional B cell and plasmablast numbers. Alpine climate treatment had a significantly greater effect on disease activity and was accompanied by a reduction in blood eosinophils and increases in memory B cells, CD8+ TemRO, CD4+ Tcm and CCR7+ Th2 subsets. CONCLUSIONS AND CLINICAL RELEVANCE: Clinically successful treatment of AD induces changes in blood B- and T cell subsets reflecting reduced chronic inflammation. In addition, multidisciplinary inpatient treatment in the alpine climate specifically affects memory B cells, CD8+ T cells and Th2 cells. These cell types could represent good markers for treatment efficacy.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos B / Clima / Linfocitos T Colaboradores-Inductores / Dermatitis Atópica / Memoria Inmunológica Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline Límite: Adolescent / Child / Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: Clin Exp Allergy Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2018 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Linfocitos B / Clima / Linfocitos T Colaboradores-Inductores / Dermatitis Atópica / Memoria Inmunológica Tipo de estudio: Clinical_trials / Diagnostic_studies / Guideline Límite: Adolescent / Child / Female / Humans / Male País/Región como asunto: Europa Idioma: En Revista: Clin Exp Allergy Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2018 Tipo del documento: Article Pais de publicación: Reino Unido